Ibere Pharmaceuticals Net Income

Ibere Pharmaceuticals posts a net income of $13M as of September 2022. That is below the sector sector average of $110M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a net income near $110M is typical. Ibere Pharmaceuticals's $13M is lower that level. That is roughly 87.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Ibere Pharmaceuticals's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for IBER's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110M), and (3) consistency with growth and profitability. This page covers the first two; Ibere Pharmaceuticals's other metric pages and overview cover the third.